HOME >> BIOLOGY >> NEWS
ENBREL rapidly, significantly improved back pain, mobility, function in ankylosing spondylitis

THOUSAND OAKS, Calif., and COLLEGEVILLE, Pa., June 19, 2003 - Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced that patients in a phase 3 clinical study assessing the efficacy and tolerability of ENBREL. (etanercept) in the treatment of active ankylosing spondylitis experienced significant and rapid reduction in back pain and morning stiffness, and improvement in spinal mobility and physical function. The data are part of a presentation at the annual meeting of European League Against Rheumatism being held this week in Lisbon, Portugal.

"A significant number of patients treated with ENBREL in this study saw a marked improvement in as early as two weeks after initiation of treatment. Patients reached maximum relief within the first two months of the study and experienced sustained results for the remainder of the six-month study," said Dr. John Davis, assistant professor of medicine at the University of California-San Francisco and associate director of the Department of Medicine Clinical Trials Center. "I am excited about these encouraging results with ENBREL, especially since it is the first treatment to show improvement in AS patients' range of spinal motion in a phase 3 study."

The multi-center, double-blind, placebo-controlled study randomized 277 patients to receive either ENBREL (25 mg twice weekly; n=138) or placebo (n=139) over a 6-month period. The primary endpoint of the pivotal Phase 3 study was the percentage of patients at 12 weeks and 24 weeks achieving a 20 percent improvement in the Assessment in Ankylosing Spondylitis Response Criteria (ASAS 20), a composite measure that includes back pain, inflammation and physical function.

At week 12, 60 percent of patients treated with ENBREL achieved the ASAS 20 compared with 27 percent of patients in the placebo group. At 24 weeks, 58 percent of patients treated with ENBREL achieved the ASAS 20 compared with 23 percent of the placebo pati
'"/>

Contact: Rebecca Hamm, Amgen
805-447-3872
Porter Novelli
20-Jun-2003


Page: 1 2 3 4

Related biology news :

1. ENBREL provided rapid and significant relief for psoriasis patients in second pivotal study
2. Once weekly ENBREL significantly reduced rheumatoid arthritis pain, inflammation & improved function
3. ENBREL combo therapy inhibits joint damage progression, offers significant RA symptom relief
4. ENBREL is first therapy approved for psoriatic arthritis
5. New Phase 2 study shows ankylosing spondylitis patients respond to ENBREL (etanercept)
6. Phase 3 psoriatic arthritis data for ENBREL (etanercept) announced at a national scientific meeting
7. Rare mutations can significantly increase risk factor for heart disease
8. Cancer health risk significantly underestimated by EPAs ambient model estimates
9. Double mastectomies significantly lower risk of breast cancer in women who are genetically at risk
10. HAART therapy significantly prolongs survival in AIDS patients with central nervous system lymphoma
11. Cognitive abilities increase significantly with time in most prematurely born children

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
(Date:4/19/2016)... 2016 The new GEZE SecuLogic ... web-based "all-in-one" system solution for all door components. It ... the door interface with integration authorization management system, and ... The minimal dimensions of the access control and the ... installations offer considerable freedom of design with regard to ...
(Date:4/14/2016)... AVIV, Israel , April 14, 2016 ... Behavioral Authentication and Malware Detection, today announced the appointment ... already assumed the new role. Goldwerger,s leadership ... BioCatch, on the heels of the deployment of its ... addition, BioCatch,s behavioral biometric technology, which discerns unique cognitive ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the leading software as ... Clinical Reach Virtual Patient Encounter CONSULT module which enables both audio and video ... trial team. , Using the CONSULT module, patients and physicians can schedule a face ...
(Date:6/27/2016)... BOSTON , June 27, 2016   Ginkgo ... biology to industrial engineering, was today awarded as ... a selection of the world,s most innovative companies. ... at scale for the real world in the ... organism engineers work directly with customers including Fortune ...
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle Marche in ... peritoneal or pleural mesothelioma. Their findings are the subject of a new article on ... biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma patients that ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
Breaking Biology Technology:
Cached News: